AstraZeneca PLC - American Depositary Shares (NQ:AZN)

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

October 06, 2025

From AstraZeneca

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure ↗

September 29, 2025

Via Stocktwits

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores ↗

October 03, 2025

Via Benzinga

Investing in These 3 Quantum Computing Stocks Could Be a Once-in-a-Lifetime Opportunity ↗

October 03, 2025

All of these rising quantum computing stars could be massive winners over the long run.

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...

Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings

October 02, 2025

The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.

Topics Economy Intellectual Property Stocks

AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? ↗

October 02, 2025

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

Topics Government World Trade

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Topics Artificial Intelligence Economy Government

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Topics ETFs

AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth

September 29, 2025

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York...

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Topics Economy

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Via Investor's Business Daily

AstraZeneca Moves From ADRs To NYSE Listing ↗

September 29, 2025

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm...

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial

September 29, 2025

From AstraZeneca

You won't need a huge amount of cash to invest in these great pharma stocks.

3 Magnificent Stocks Under $100 to Buy Right Now ↗

September 27, 2025

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent...

Your AstraZeneca Medicine Could Be Cheaper As Much As 70% ↗

September 26, 2025

Via Benzinga

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions

September 26, 2025

From AstraZeneca

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre ↗

September 25, 2025

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Via Benzinga

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

September 24, 2025

From AstraZeneca

AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗

September 22, 2025

Via Benzinga

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Topics Economy Intellectual Property

Is the Market Bullish or Bearish on AstraZeneca? ↗

September 22, 2025

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

Topics Artificial Intelligence Economy Intellectual Property

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

Topics Artificial Intelligence Economy Intellectual Property

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...